Commonwealth Equity Services, LLC Lineage Cell Therapeutics, Inc. Transaction History

Commonwealth Equity Services, LLC

$77.2 Billion
Q3 2025

A detailed history of Commonwealth Equity Services, LLC transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Commonwealth Equity Services, LLC holds 100,922 shares of LCTX stock, worth $191,751. This represents 0.0% of its overall portfolio holdings.

Number of Shares

100,922

Previous 61,522 64.04%

Holding current value

$191,751

Previous $56,000 205.36%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Oct 22, 2025	BUY	$0.87 - $1.79 $34,278 - $70,526	39,400 Added 64.04%	100,922 $171,000
Q2 2025 Aug 06, 2025	BUY	$0.39 - $1.13 $1,097 - $3,179	2,814 Added 4.79%	61,522 $56,000
Q4 2024 Feb 10, 2025	BUY	$0.5 - $0.95 $5,223 - $9,924	10,447 Added 21.65%	58,708 $30,000
Q3 2024 Oct 18, 2024	BUY	$0.8 - $1.12 $400 - $560	500 Added 1.05%	48,261 $44,000
Q4 2023 Feb 06, 2024	SELL	$0.91 - $1.35 $6,116 - $9,073	-6,721 Reduced 12.34%	47,761 $52,000

Q3 2023 Oct 23, 2023	BUY	$1.16 - $1.53 $3,479 - $4,590	3,000 Added 5.83%	54,482 $64,000
Q2 2023 Aug 10, 2023	BUY	$1.26 - $1.53 $3,771 - $4,579	2,993 Added 6.17%	51,482 $73,000
Q1 2023 May 11, 2023	SELL	$1.2 - $1.53 $600 - $765	-500 Reduced 1.02%	48,489 $72,000
Q4 2022 Feb 07, 2023	BUY	$1.02 - $1.5 $6,118 - $8,998	5,999 Added 13.95%	48,989 $57,000
Q3 2022 Nov 14, 2022	SELL	$1.13 - $1.77 $2,824 - $4,425	-2,500 Reduced 5.5%	42,990 $48,000
Q2 2022 Jul 19, 2022	BUY	$1.12 - $1.61 $1 - $1	1 Added 0.0%	45,490 $71,000
Q1 2022 May 04, 2022	BUY	$1.21 - $2.48 $8,300 - $17,012	6,860 Added 17.76%	45,489 $70,000
Q4 2021 Jan 31, 2022	SELL	$1.84 - $2.68 $9,770 - $14,230	-5,310 Reduced 12.08%	38,629 $94,000
Q3 2021 Oct 29, 2021	SELL	$2.26 - $2.86 $23,503 - $29,744	-10,400 Reduced 19.14%	43,939 $110,000
Q2 2021 Aug 11, 2021	BUY	$2.17 - $3.0 $13,050 - $18,042	6,014 Added 12.44%	54,339 $154,000
Q1 2021 May 04, 2021	SELL	$1.77 - $3.1 $73,462 - $128,662	-41,504 Reduced 46.2%	48,325 $113,000
Q4 2020 Feb 11, 2021	SELL	$0.95 - $1.83 $1,510 - $2,909	-1,590 Reduced 1.74%	89,829 $158,000
Q3 2020 Nov 05, 2020	BUY	$0.75 - $1.09 $4,500 - $6,540	6,000 Added 7.02%	91,419 $85,000
Q2 2020 Aug 12, 2020	BUY	$0.71 - $1.18 $7,519 - $12,497	10,591 Added 14.15%	85,419 $74,000
Q1 2020 May 11, 2020	BUY	$0.6 - $1.58 $4,690 - $12,352	7,818 Added 11.67%	74,828 $61,000
Q4 2019 Feb 05, 2020	SELL	$0.54 - $1.01 $25,567 - $47,821	-47,348 Reduced 41.4%	67,010 $59,000
Q3 2019 Oct 30, 2019	BUY	$0.85 - $1.24 $97,204 - $141,803	114,358 New	114,358 $112,000

Others Institutions Holding LCTX

# of Institutions

128

Shares Held

96M

Call Options Held

251K

Put Options Held

50K

View Full List

About Lineage Cell Therapeutics, Inc.

Ticker LCTX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 169,755,008
Market Cap $323M
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...

More about LCTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Commonwealth Equity Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Commonwealth Equity Services, LLC with notifications on news.

Account

Commonwealth Equity Services, LLC Lineage Cell Therapeutics, Inc. Transaction History